Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol “PRTG” Portage Biotech Inc., a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares from the Canadian Securities Exchange .Since Portage’s Shares began trading on the …
Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol “PRTG”
Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares (“Shares”) from the Canadian Securities Exchange (the “CSE”).